Comprehensive assessment and network analysis of the emerging genetic susceptibility landscape of prostate cancer

Cancer Informatics

Volumn 12, Issue , 2013, Pages 175-191

  Hicks, Chindo ^a,b   Miele, Lucio ^a   Koganti, Tejaswi ^b   Vijayakumar, Srinivasan ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Prostate cancer GWAS network pathway analysis

Indexed keywords

ANDROGEN; JANUS KINASE 2; SOMATOMEDIN C; STAT3 PROTEIN;

ANDROGEN SYNTHESIS; ARTICLE; GENE REGULATORY NETWORK; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IGF 1 GENE; JAK2 GENE; MOLECULAR MECHANICS; NONHUMAN; PROSTATE CANCER; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STAT3 GENE; TUMOR GENE;

EID: 84883311517     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S12128     Document Type: Article

References (36)

1. American Cancer Society. Cancer facts and figures 2012. Atlanta: American Cancer Society; 2012. http://www.cancer.org/cancer/cancerbasics/index.
2. Hindorff LA, Sethupathy P, Junkins HA, etal. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106(23):9362-7.
3. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature. 2009;461:218-23.
4. Luo L, Peng G, Zhu Y, Dong H, Amos CI, Xiong M. Genome-wide gene pathway analysis. Europ J Hum Genet. 2010;18:1045-53.
5. Hicks C, Asfour R, Pannuti A, Miele L. An integrative genomics approach to biomarker discovery in breast cancer. Cancer Inform. 2011;10:185-204.
6. Ioannidis JP, Boffetta P, Little J, etal. Assessment of cumulative evidence on genetic associations: Interim guidelines. Intl J Epidemiol. 2008; 37:120-32.
7. Khoury MJ, Bertram I, Boffetta P, etal. Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation in human diseases. Am J Epidemiol. 2009;170:269-79.
8. Sagoo GS, Little J, Higgins JP. Systematic reviews of genetic association studies. Human Genome Epidemiology Network. PLoS Med. 2009;6:e28.
9. Moher D, Liberati A, Tetzlaff J. Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9.
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, etal. The PRISMA statement for reporting systematic reviews and meta-analyses studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
11. Hicks C, Kumar R, Pannuti A, etal. An integrative genomics approach for associating GWAS information with triple-negative breast cancer. Cancer Inform. 2013;12:1-20.
12. Zhang B, Beeghly-Fadiel A, Long J, Wei Z. Genetic variants associated with breast-cancer risk: Comprehensive research synopsis, meta-analysis, and epidemiology evidence. Lancet. 2011;12:477-88.
13. Grasso CS, Wu YM, Robinson DR, etal. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239-43.
14. Berger MF, Lawrence MS, Demichelis F, etal. The genomic complexity of primary human prostate cancer. Nature. 2011;470(7333):214-20.
15. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363(2):166-76.
16. Neal BM, Sham PC. The future of association studies. Gene-based analysis and replication. Am J Hum Genet. 2004;75:353-62.
17. Ashburner M, Ball CA, Blake JA, etal. Gene ontology: tool for the unification of biology. The Gene Ontolgy Consortium. Nat Genet. 2000;25(1):25-9.
18. Ingenuity Pathways Analysis (IPA) system. Redwood, CA: Ingenuity Systems, Inc.; http://www.ingenuity.com/.
19. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434-42.
20. Chanock SJ, Manolio T, Boehnke M, etal; NCI-NHGRI Working Group on Replication in Association Studies. Replicating genotype-phenotype associations. Nature. 2007;447:655-60.
21. Ioannidis JP. Non-replication and inconsistency in the genome-wide association setting. Hum Hered. 2007;64:203-13.
22. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet. 2006;7:781-91.
23. Pompanon F, Bonin A, Bellemain E, Taberlet P. Genotyping errors: causes, consequences and solutions. Nat Rev Genet. 2005;6:847-59.
24. Clayton DG, Walker NM, Smyth DJ, etal. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat Genet. 2005;37:1243-6.
25. Page GP, George V, Page PZ, Allison DB. Are there yet? Deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits. Am J Hum Genet. 2003;73:711-9.
26. Kwon EM, Holt SK, Fu R, etal. Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer Epidemiol. 2012;36:347-53.
27. Feng J, Sun J, Kim S-T, Lu Y, etal. A genome-wide survey over the ChIP-On-Chip identified androgen receptor-binding genomic regions identifies a novel prostate cancer susceptibility locus at 12q13.13. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2396-403.
28. Kaarbo M, Klokk TI, Saatcioglu F. Androgen signaling and its intervention with other signaling pathways in prostate cancer. Bioessays. 2007;29:1227-38.
29. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human kallikrein 2 (hk2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci. 1998;35:275-368.
30. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8:440-8.
31. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endoc Rev. 2004;25(2):276-308.
32. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253-61.
33. Knusen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 2010;21(5):315-23.
34. Papatsoris A, Karamouzis MV, Papavassiliou AG. Novel insights into the implication of the IGF-1 network in prostate cancer. Trends Mol Med. 2005;11(2):52-5.
35. Dagvadorj A, Collins S, Jomain J-B, etal. Autocrine prolactin promotes cancer cell growth via janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology. 2007;148:3089-101.
36. Amin Al, Olama A, Kote-Jarai Z, Schumacher FR, etal. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet. 2013;22(2):408-15.